Back to results
US 12,180,282 B2Granted
Anti-PD-L1 antibodies
AssigneesWUXI Biologics (Shanghai) Co., Ltd., Wuxi Biologics Ireland Limited
InventorsYong Zheng, Jing Li, Zhisheng Chen
Life of this patent
Estimating the term…
Abstract
The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
Claims18
An isolated polynucleotide encoding for an anti-PD-L1 antibody or an antigen binding fragment thereof comprising:
- a) a heavy chain variable region comprising SEQ ID NO:
- 1, SEQ ID NO:
- 3, and SEQ ID NO:
- 5;
- and a light chain variable region comprising SEQ ID NO:
- 7, SEQ ID NO:
- 9, and SEQ ID NO:
- 11;
- b) a heavy chain variable region comprising SEQ ID NO:
- 13, SEQ ID NO:
- 15, and SEQ ID NO:
- 17;
- and a light chain variable region comprising SEQ ID NO:
- 19, SEQ ID NO:
- 21, and SEQ ID NO:
- 23;
- c) a heavy chain variable region comprising SEQ ID NO:
- 25, SEQ ID NO:
- 27, and SEQ ID NO:
- 29;
- and a light chain variable region comprising SEQ ID NO:
- 31, SEQ ID NO:
- 33, and SEQ ID NO:
- 35:
- or
- d) a heavy chain variable region comprising SEQ ID NO:
- 37, SEQ ID NO:
- 39, and SEQ ID NO:
- 41;
- and a light chain variable region comprising SEQ ID NO:
- 19, SEQ ID NO:
- 21, and SEQ ID NO:
- 23.
30 more elements
Dependencies are inferred from the claim text.